PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+16.3%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$122M
AUM Growth
-$94.3M
(-44%)
Cap. Flow
-$101M
Cap. Flow
% of AUM
-82.94%
Top 10 Holdings %
Top 10 Hldgs %
59.86%
Holding
56
New
14
Increased
5
Reduced
18
Closed
19
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$6.12M |
| 2 |
Kezar Life Sciences
KZR
|
+$4.39M |
| 3 |
Cellectis
CLLS
|
+$3.41M |
| 4 |
Oscar Health
OSCR
|
+$3.35M |
| 5 |
Solid Biosciences
SLDB
|
+$2.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Organogenesis Holdings
ORGO
|
+$27.2M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$25.8M |
| 3 |
Prothena Corp
PRTA
|
+$9.24M |
| 4 |
Baxter International
BAX
|
+$9.15M |
| 5 |
Cigna
CI
|
+$8.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.63% |
| 2 | Energy | 1.37% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Beam Therapeutics
BEAM
$2.44B
| $1.36M | 1.11% |
+17,000
| New | +$1.62M |
2021 Q1
0 quarters
|
|
|
ALXN
27
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.33M | 1.09% |
8,685
-167,053
| -95% | -$25.8M |
2020 Q1
4 quarters
|
|
|
ONCR
28
DELISTED
Oncorus, Inc.
ONCR
| $986K | 0.81% |
+70,807
| New | +$1.47M |
2021 Q1
0 quarters
|
|
|
APTO
29
DELISTED
Aptose Biosciences, Inc.
APTO
| $896K | 0.73% |
333
-1,500
| -82% | -$2.97M |
2020 Q2
3 quarters
|
|
30
ADMA Biologics
ADMA
$2.32B
| $876K | 0.72% |
497,842
-385,372
| -44% | -$882K |
2020 Q1
4 quarters
|
|
31
Exicure
XCUR
$7.92M
| $601K | 0.49% |
+1,839
| New | +$633K |
2021 Q1
0 quarters
|
|
|
SIOX
32
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $537K | 0.44% |
+205,900
| New | +$582K |
2021 Q1
0 quarters
|
|
|
33
Baxter International
BAX
$12.8B
| $489K | 0.4% |
5,800
-115,275
| -95% | -$9.15M |
2020 Q2
3 quarters
|
|
|
ODT
34
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $402K | 0.33% |
+117,621
| New | +$2.22M |
2021 Q1
0 quarters
|
|
35
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $329K | 0.27% |
+5,202
| New | +$239K |
2021 Q1
0 quarters
|
|
|
36
Organogenesis Holdings
ORGO
$147M
| $278K | 0.23% |
15,232
-2,008,209
| -99% | -$27.2M |
2019 Q4
5 quarters
|
|
37
Assembly Biosciences
ASMB
$418M
| $260K | 0.21% |
+4,708
| New | +$312K |
2021 Q1
0 quarters
|
|
38
AC Immune
ACIU
$239M
| – | – |
-8,942
| Closed | -$46K | – |
|
39
PUT
ARK Genomic Revolution ETF
ARKG
$2.05B
| – | – |
-10,000
| Closed | -$933K | – |
|
|
40
PUT
Beam Therapeutics
BEAM
$2.44B
| – | – |
-10,000
| Closed | -$816K | – |
|
|
41
Cigna
CI
$76.5B
| – | – |
-41,418
| Closed | -$8.62M | – |
|
42
Centene
CNC
$34.7B
| – | – |
-40,000
| Closed | -$2.4M | – |
|
43
Dianthus Therapeutics
DNTH
$4.18B
| – | – |
-7,853
| Closed | -$985K | – |
|
44
Immatics
IMTX
$1.07B
| – | – |
-104,999
| Closed | -$1.13M | – |
|
45
Mirum Pharmaceuticals
MIRM
$5.19B
| – | – |
-60,250
| Closed | -$1.05M | – |
|
46
Moderna
MRNA
$90.3B
| – | – |
-174
| Closed | -$18K | – |
|
|
47
CALL
Prothena Corp
PRTA
$430M
| – | – |
-175,200
| Closed | -$2.1M | – |
|
48
uniQure
QURE
$1.45B
| – | – |
-53,900
| Closed | -$1.95M | – |
|
49
PUT
Twist Bioscience
TWST
$9.82B
| – | – |
-25,000
| Closed | -$3.53M | – |
|
50
PUT
Veracyte
VCYT
$3.5B
| – | – |
-35,000
| Closed | -$1.71M | – |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q1 2021 Portfolio in Review
As of Q1 2021, Prosight Management held 56 positions worth $122M, down 44% from $216M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Prosight Management withdrew a net $101M in Q1 2021, closing 19 positions and reducing 18 holdings. Its most notable exit was Cigna, an estimated $8.62M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 88% a quarter earlier, followed by Energy and Technology.
Against the trend, Prosight Management opened a new position in Lakefront Biotherapeutics American Depositary Shares worth $5.12M.
- Prosight Management's largest Q1 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 66,419 shares worth $5.12M.
- Prosight Management added most to Vertex Pharmaceuticals in Q1 2021, an estimated $2.08M increase.
- Prosight Management's biggest Q1 2021 reduction was Organogenesis Holdings, cutting an estimated $27.2M.
- Prosight Management fully exited Cigna in Q1 2021, selling an estimated $8.62M.
- Prosight Management's ten largest holdings make up 60% of its $122M portfolio in Q1 2021.
- Prosight Management opened 14 new positions and closed 19 in Q1 2021.
- Prosight Management's portfolio value fell 44% quarter-over-quarter to $122M.
Based on Prosight Management's 13F filing for Q1 2021, filed 14 May 2021.